The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV gen...otype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014more
In this review, the editors will investigate the impact of eight WASH interventions in preventing (reducing the risk of) and controlling outbreaks in LMIC, with particular focus on three diseases of current concern to the response community – cholera, Ebola, and Hepatitis E. Additionally, we will ...explore economic outcomes related to WASH interventions within an outbreakmore
The key updates include: content update in various sections based on new evidence; design changes for enhanced usability; a streamlined and simplified clinical assessment that includes an algorithm for follow-up; inclusion of two new modules
- Essential Care and Practice that includes general guid...elines and Iminterventions and implementation module to support the proposed interventions by necessary infrastructure and resources; and, revised modules for Psychoses, Child and Adolescent Mental and Behavioural Disorders and Disorders due to Substance Usemore
The CHS is a voluntary and measurable standard, which means its application can be objectively assessed. The CHS Verification Scheme allows organisations to measure the extent to which they have successfully applied the CHS requirements, and allows them, to demonstrate that they have done so. The Sc...heme offers four verification options; although each option is stand alone, the indicators used in the self-assessment are common to all options.more
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.more